Skip to main content

Table 2 Demographic, clinical and MRI characteristics, and lipid profiles of patient subsets with and without statins.

From: Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis

Variable No Statins Statins p-value
Females: Males (% Female) 301: 81 (78.8%) 69: 40 (63.3%) < 0.002§
MS course:    0.075
Relapsing-remitting 314 81 (74.3%)  
Secondary progressive (82.2%)   
Primary progressive 55 (12.8%)
13 (3.4%)
27 (24.8%)
1 (0.9%)
 
Age*, years 45.3 ± 10.7 53.4 ± 8.4 < 0.001
Disease duration*, years 11.9 ± 9.7 16.2 ± 11.0 < 0.001
Median EDSS* (IQR) 2.5 (2.0) 3.50 (3.50) < 0.001#
MSSS 3.67 ± 2.51 4.15 ± 2.18 0.061
Time to follow-up, years 2.13 ± 1.0 2.22 ± 1.0 0.43
Body mass index, kg/m2 27.4 ± 6.5 29.1 ± 6.5 0.013
HDL, mg/dL 55.6 ± 16.6 53.7 ± 16.5 0.72
LDL, mg/dL 115 ± 30.8 118 ± 39.0 0.62
Total cholesterol, mg/dL 196 ± 36.0 201 ± 44.7 0.38
Triglycerides, mg/dL 128 ± 84.0 149 ± 75.5 0.15
Cholesterol to HDL ratio 3.81 ± 1.28 4.00 ± 1.40 0.60
Presence of CEL
CEL number
CE-LV, cm3
25/156 (16%)
0.60 ± 2.3
0.035 ± 0.15
4/40 (10%)
0.23 ± 0.86
0.019 ± 0.080
0.47
0.026
0.035
T2-LV, cm3 13.6 ± 14.7 16.0 ± 14.7 0.30
T1-LV, cm3 2.7 ± 5.1 4.5 ± 6.3 0.019
BPF 0.858 ± 0.027 0.848 ± 0.035 0.056
  1. Statin usage data were available for 491 patients.
  2. * At time of baseline lipid profile assessment.
  3. § Fisher exact test
  4. Fisher exact test for presence of secondary progressive or progressive forms of MS.
  5. # Mann-Whitney test
  6. p-values for statin variable from regression analyses with sex, disease duration and statin use as predictor variables.